Abstract:Abstract Background: The immunotherapy for different types of cancers that targeting programmed death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) has highlighted the importance of suppressing specific T cell responses. Recently, several studies have shown that the expression level of PD-L1 in tumor cells is positively correlated with tumor metastasis as well as recurrence rate. The potent effects of post-translational modifications (PTMs) for PD-L1, such as ubiquitination, glycosylation, phosphorylation and palmitoylation, have been reported to be related to immunosuppression. However, the regulation of PD-L1 degradation in cancers is still not well understood. In this paper, we mainly investigate the deubiquitination regulation of PD-L1. Methods: The protein levels of PD-L1 and USP21 were detected by Immunoblotting and immunohistochemistry. The interaction between PD-L1 and USP21 was determined by co-immunoprecipitation. The deubiquitination of PD-L1 was determined by in vitro deubiquitination assay. The deubiquitination sites of PD-L1 were identified by mass spectrometry analysis. The expression of mRNA in target tissues was presented by bioinformatics analysis.Results: Overexpression of USP21 significantly increased PD-L1 abundance and knockdown of USP21 induced degradation of PD-L1. In vitro deubiquitination assay showed that USP21-WT reduced polyubiquitin chains from PD-L1 while USP21-C221A did not. Furthermore, five lysines in intracellular segment of PD-L1 are potential deubiquitin sites and cancer-derived mutations of PD-L1 in Asp276 have the ability to enhance the deubiquitination of PD-L1 mediated by USP21. Finally, we found that USP21 is the frequently amplified deubiquitinase in lung cancer, especially in lung squamous cell carcinoma, and its amplification co-occurs with the upregulation of PD-L1 levels. Moreover, IHC analysis showed stronger staining of PD-L1 and USP21 in lung cancer samples than adjacent tissues. Conclusion: We identified USP21 as a novel deubiquitinase of PD-L1. Hopefully, targeting PD-L1 by inhibiting USP21 might be a potentially novel strategy for the treatment of lung cancer.

Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma.

The Deubiquitinase USP22 Regulates PD-L1 Degradation in Human Cancer Cells.

Deubiquitination and Stabilization of PD-L1 by USP21

Ubiquitin-specific protease 14 targets PFKL-mediated glycolysis to promote the proliferation and migration of oral squamous cell carcinoma

Comprehensive Analysis of Ubiquitin‐specific Protease 1 Reveals Its Importance in Hepatocellular Carcinoma

The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization.

USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1

USP8 Deubiquitinates PD-L1 to Suppress the Immunotherapy of Pancreatic Ductal Carcinoma

USP14 promotes the cancer stem‐like cell properties of OSCC via promoting SOX2 deubiquitination

As a Novel Tumor Suppressor, LHPP Promotes Apoptosis by Inhibiting the PI3K/AKT Signaling Pathway in Oral Squamous Cell Carcinoma

Deubiquitination and Stabilization of PD-L1 by USP21.

Deubiquitinase USP9X promotes cell migration, invasion and inhibits apoptosis of human pancreatic cancer.

USP9X-mediated Deubiquitination of B-cell CLL/lymphoma 9 Potentiates Wnt Signaling and Promotes Breast Carcinogenesis

Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma

USP10 promotes pancreatic ductal adenocarcinoma progression by attenuating FOXC1 protein degradation to activate the WNT signaling pathway

Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer

[Levels of Programmed Death-1 and Programmed Death Ligand-1 in the Peripheral Blood of Patients with Oral Squamous Cell Carcinoma and Its Clinical Implications].

Ubiquitin-specific peptidase 10, a deubiquitinating enzyme: Assessing its role in tumor prognosis and immune response

Deubiquitinating enzyme USP44 suppresses hepatocellular carcinoma progression through inhibiting Hedgehog signaling and PDL1 expression

The Deubiquitinating Enzyme USP44 Suppresses Hepatocellular Carcinoma Progression by Inhibiting Hedgehog Signaling and PDL1 Expression

The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants